Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Onpattro Market Size Forecast: How Large Could The Market Become By 2030?
Advances in RNA-based drug development, a rise in diagnosed cases of hATTR amyloidosis, regulatory endorsements for gene-silencing treatments, the broadening network of specialty infusion centers, and clinical confirmation of patisiran’s effectiveness fueled growth during the historical period.
The expansion of next-generation RNA therapeutics, greater investment in rare disease pipelines, an intensified emphasis on personalized medicine, the development of subcutaneous delivery options, and the growing implementation of genetic screening programs are all driving growth during the forecast period. Key trends expected to shape this period include the rising use of RNA interference therapies, increased attention on treating rare genetic disorders, broader availability of precision gene silencing methods, enhanced patient outcomes in amyloidosis management, and the growing incorporation of advanced infusion therapies into clinical practice.
Download A Free Sample Report For Comprehensive Market Insights:
Onpattro Market Growth Drivers And Industry Catalysts
The ongoing increase in cases of hereditary transthyretin-mediated amyloidosis is anticipated to drive the expansion of the Onpattro market in the coming years. Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare genetic condition characterized by mutated TTR proteins that accumulate as harmful deposits, leading to damage in the nerves and heart. This rising prevalence is fueled by advancements in diagnostic techniques, expanded genetic testing, and heightened awareness, which together uncover a greater number of cases. Onpattro is employed to address this disorder by inhibiting the transthyretin (TTR) gene, thereby reducing amyloid protein formation and averting organ impairment. For example, in February 2024, Verywell Health, a US-based health information resource, reported that hereditary transthyretin-mediated amyloidosis impacts 5,500 to 38,500 people worldwide, while U.S. estimates note 104 to 3,847 cases of hATTR with polyneuropathy, pointing to substantial underdiagnosis. Consequently, the growing prevalence of hereditary transthyretin-mediated amyloidosis is fueling the development of the Onpattro market.
Onpattro Market Categorization By Product Type And Application
The onpattro market covered in this report is segmented –
1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses
2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies
3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers
Onpattro Market Trends Influencing Long-Term Demand
A major development within the onpattro market revolves around broadening the drug’s approved indications through supplemental applications, a strategy designed to unlock greater commercial opportunity and address a more diverse patient population. These regulatory submissions typically aim to expand a medication’s authorized uses, whether by adding new conditions, targeting different patient groups, or introducing alternative formulations, thereby extending its therapeutic scope and revenue potential. As an example, in February 2023, Alnylam Pharmaceuticals, a biopharmaceutical company headquartered in the United States, confirmed that its Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran) had been accepted. This therapy is intended for cardiomyopathy linked to transthyretin amyloidosis (ATTR). ONPATTRO functions as an RNA interference (RNAi) therapeutic, engineered to precisely target the transthyretin (TTR) protein, whose abnormal buildup in individuals with ATTR amyloidosis can give rise to serious issues like cardiomyopathy. Originally sanctioned in 2018 for treating hereditary ATTR amyloidosis-induced polyneuropathy, the latest sNDA submission draws on data from the Phase III APOLLO-B trial, which revealed that patisiran was associated with significant enhancements in functional capacity and life quality among cardiomyopathy patients relative to a placebo.
Onpattro Market Company Landscape And Strategic Competition
Major companies operating in the onpattro market are Alnylam Pharmaceuticals Inc.
Access The Complete Onpattro Market Report:
Onpattro Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the onpattro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model